文献速递脑血管病神经重症与神经感染

挪威移动卒中单元诊疗的成本效益

Cost-Effectiveness of Mobile Stroke Unit Care in Norway.
PubMed 文献 · Stroke · 2022-07-13

本研究基于挪威移动卒中单元研究Treat-NASPP的疗效数据,构建马尔可夫模型从终生视角评估移动卒中单元诊疗相比常规诊疗的增量成本、健康获益与成本效益。结果显示移动卒中单元诊疗每例患者预期增加0.065个质量调整生命年;每年治疗约260例缺血性卒中患者时,增量成本效益比约为385 000挪威克朗(43 780美元)每质量调整生命年。结论认为在挪威环境下移动卒中单元诊疗可能具有成本效益,但取决于每辆车每年治疗相当数量的急性缺血性卒中患者。

要点

  • 移动卒中单元诊疗每例患者预期增加0.065个质量调整生命年。
  • 每年治疗约260例缺血性卒中患者时,增量成本效益比约为385 000挪威克朗(43 780美元)每质量调整生命年。
  • 增量成本效益比随年治疗量变化:每年治疗100例时约1 000 000挪威克朗(113 700美元)每质量调整生命年,每年治疗300例时约340 000挪威克朗(38 660美元)每质量调整生命年。

核心结论

  • 在挪威环境下,移动卒中单元诊疗相比常规诊疗可能具有成本效益,但取决于每辆车每年治疗相当高数量的急性缺血性卒中患者。

研究设计与样本

  • 本研究基于挪威移动卒中单元研究Treat-NASPP的疗效数据,构建马尔可夫模型,将移动卒中单元诊疗带来的治疗时间缩短和溶栓率提高与患者终生功能结局相联系,估算增量成本、健康获益和成本效益,并估算在挪威公共资助医疗体系中移动卒中单元诊疗具有成本效益所需的最低利用水平。

主要发现

  • 移动卒中单元诊疗相比标准诊疗,每例患者预期增加0.065个质量调整生命年。
  • 每年治疗约260例缺血性卒中患者时,移动卒中单元诊疗相比标准诊疗的增量成本效益比约为385 000挪威克朗(43 780美元)每质量调整生命年。
  • 增量成本效益比随年治疗量变化:每年治疗100例时约为1 000 000挪威克朗(113 700美元)每质量调整生命年,每年治疗300例急性缺血性卒中时约为340 000挪威克朗(38 660美元)每质量调整生命年。

关键数值与推荐

  • 移动卒中单元诊疗每例患者预期增加0.065个质量调整生命年。
  • 每年治疗约260例缺血性卒中患者时,增量成本效益比约为385 000挪威克朗(43 780美元)每质量调整生命年。
  • 每年治疗100例时增量成本效益比约为1 000 000挪威克朗(113 700美元)每质量调整生命年;每年治疗300例时约为340 000挪威克朗(38 660美元)每质量调整生命年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute ischemic stroke treatment in mobile stroke units (MSUs) reduces time-to-treatment and increases thrombolytic rates, but implementation requires substantial investments. We wanted to explore the cost-effectiveness of MSU care incorporating novel efficacy data from the Norwegian MSU study, Treat-NASPP (the Norwegian Acute Stroke Prehospital Project). METHODS: We developed a Markov model linking improvements in time-to-treatment and thrombolytic rates delivered by treatment in an MSU to functional outcomes for the patients in a lifetime perspective. We estimated incremental costs, health benefits, and cost-effectiveness of MSU care as compared with conventional care. In addition, we estimated a minimal MSU utilization level for the intervention to be cost-effective in the publicly funded health care system in Norway. RESULTS: MSU care was associated with an expected quality-adjusted life-year-gain of 0.065 per patient, compared with standard care. Our analysis suggests that about 260 patients with ischemic stroke need to be treated with MSU annually to result in an incremental cost-effectiveness ratio of about NOK385 000 (US$43 780) per quality-adjusted life-year for MSU compared with standard care. The incremental cost-effectiveness ratio varies between some NOK1 000 000 (US$113 700) per quality-adjusted life-year if an MSU treats 100 patients per year and to about NOK340 000 (US$38 660) per quality-adjusted life-year if 300 patients with acute ischemic stroke are treated. CONCLUSIONS: MSU care in Norwegian settings is potentially cost-effective compared with conventional care, but this depends on a relatively high annual number of treated patients with acute ischemic stroke per vehicle. These results provide important information for MSU implementation in government-funded health care systems.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Lund UH, Stoinska-Schneider A, Larsen K, et al. Cost-Effectiveness of Mobile Stroke Unit Care in Norway. Stroke. 2022. PMID: 35862205. doi:10.1161/STROKEAHA.121.037491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。